Associate Editors-in-Chief

Ling Lu, MD, PhD

Dr. Ling Lu is Division of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Prof. Ling Lu is a surgeon at Division of Liver Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. He is involved in researches concerning liver surgery and transplantation immunology. In the past 15 years, Prof. Lu focuses on the immunology of liver transplantation, especially on the clinical application of regulatory T cells for transplant patients. In the past 5 years, some of these studies have been translated into the clinic for the patients after living donor liver transplantation surgery.

He has peer reviewed many publications for main scientific journals, such as Plos one, Lancet Global Health, Journal of Cellular and Molecular Medicine, and Grant reviews of National Science Foundation of China (NSFC).

Franco M. Muggia, MD

Professor of Medicine, New York University School of Medicine, New York, NY, USA

Dr. Muggia was a senior investigator at the National Cancer Institute from 1969 to 1972, and also Associate Director for the Cancer Therapy Evaluation Program at NCI from 1975 to 1979, during which time he was responsible for the clinical development of cisplatin. He subsequently headed Medical Oncology at New York University (1979-1986; 1996-2009) and the University of Southern California Comprehensive Cancer Center (1986-1996), while also serving as Associate Director for Clinical Investigations at these institutions, and Director of the NYU Kaplan Cancer Center (1997-9). He has led the combined fellowship training program in Hematology/Oncology at New York University Cancer Institute (2006-2010). Other positions and honors include the following: Principal Investigator of a Bristol Myers Squibb Foundation Award to the University of Southern California; Chairman of the Medical Oncology Committee of the Gynecology Oncology Group; Chairman and Medical Director of the Chemotherapy Foundation; member of the executive committee of the Scientific Advisory Board of the American Italian Foundation for Cancer Research, and of the Lynne Cohen Foundation for Ovarian Cancer Research. Also he has co-led international symposia: on Platinum Coordination Compounds in Cancer (2003), and on Hereditary Breast and Ovarian Cancers (2009, 2011). He has authored numerous scientific articles, books, and book chapters. His present interests include: development of anticancer drugs, intraperitoneal therapy for gynecologic and gastrointestinal cancers, and early identification and prevention of cancers in women at high-risk.

Jia Wei, MD, PhD

The Comprehensive Cancer Center, Affiliated Drum Tower Hospital to Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China

Dr. Jia Wei is now working as a medical oncologist and Associated Professor in the Comprehensive Cancer Center, Affiliated Drum Tower Hospital to Medical School of Nanjing University. Dr. Wei is the vice director of cancer center and the Clinical Cancer Institute of Nanjing University. She is also doctoral supervisor of Nanjing University. She received more than one-year training in personalized medicine based on molecular biology under the supervision of Dr. Rafael Rosell from 2007. She is the inaugural STO-CSCO International Fellow and received trainings at Harvard’s Brigham & Women’s Hospital, Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute, Mayo Clinic and the National Cancer Institute. Dr. Wei has experiences of translational researches in gastric cancer. She has authored or co-authored 64 scientific articles in peer-reviewed journals, as well as several book chapters and presentations.

Ke-Da Yu, MD, PhD (Breast Cancer)

Department of Breast Surgery, Shanghai Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.

Medical College, with the doctoral thesis of breast carcinogenesis. After graduation, he worked at Fudan University Shanghai Cancer Center. From 2011 to 2012, he went to Baylor College of Medicine and the Methodist Hospital as a visiting scholar. Then he returned back to Fudan University Shanghai Cancer Center and served as the deputy director of Department of Breast Surgery. As a surgical oncologist and translational research investigator, he worked in the field of precise diagnosis and treatment of breast cancer according to intrinsic subtypes, especially for the triple-negative breast cancer, which has poor biological characteristics and unfavorable prognosis. He had published more than 90 articles in the leading academic journals including Nat Commun, Cancer Res, Clin Cancer Res, Lancet Oncol, J Clin Oncol, and BMC Med, with the H-index of 23 and being cited for more than 1700 times. His achievements were awarded the Shanghai Municipality S&T Progress Award First Prize, Meiji Dairy Science Award, etc. He got four research grants supported by Natural Science Foundation of China (Excellent Youth Project, 81722032; General Project, 81672600; General Project, 81370075; Youth Project, 81001169).